Prevalence and impact of visual aura in migraine and probable migraine: a population study

Kyung Min Kim1,3, Byung-Kun Kim2,3, Wonwoo Lee1, Heewon Hwang1, Kyoung Heo1 & Min Kyung Chu1*

Visual aura (VA) presents in 98% of cases of migraine with aura. However, data on its prevalence and impact in individuals with migraine and probable migraine (PM) are limited. Data from the nationwide, population-based Circannual Change in Headache and Sleep Study were collected. Participants with VA rating scale scores ≥ 3 were classified as having VA. Of 3,030 participants, 170 (5.6%) and 337 (11.1%) had migraine and PM, respectively; VA prevalence did not differ between these cohorts (29.4% [50/170] vs. 24.3% [82/337], p = 0.219). Participants with migraine with VA had a higher headache frequency per month (4.0 [2.0–10.0] vs. 2.0 [1.0–4.8], p = 0.014) and more severe cutaneous allodynia (12-item Allodynia Symptom Checklist score; 3.0 [1.0–8.0] vs. 2.0 [0.0–4.8], p = 0.046) than those without VA. Participants with PM with VA had a higher headache frequency per month (2.0 [2.0–8.0] vs. 2.0 [0.6–12.0], p < 0.001), greater disability (Migraine Disability Assessment score; 10.0 [5.0–26.3] vs. 5.0 [2.0–12.0], p < 0.001), and more severe cutaneous allodynia (12-item Allodynia Symptom Checklist score, 2.5 [0.0–6.0] vs. 0.0 [0.0–3.0], p < 0.001) than those without VA. VA prevalence was similar between migraine and PM. Some symptoms were more severe in the presence of VA.

Aura is a complex, reversible neurological manifestation that occurs during or before the onset of the headache phase in migraine1. The third edition of the International Classification of Headache Disorders (ICHD-3) has defined migraine with aura (MA) as a condition with fully reversible visual, sensory, motor, speech and/or language, brainstem, and retinal symptoms. Visual aura (VA) is the most common form of aura in MA, occurring either alone or in combination with other auras in 98% of cases2–4. MA differs from migraine without aura (MO) in terms of the prevalence, comorbidities, triggering factors, and clinical characteristics5–8.

Epidemiological studies have reported the prevalence and impact of aura in general populations9–11. These studies used questionnaires to identify the aura symptoms; however, most questionnaires were not validated through a comparison between their results and the doctor’s diagnosis of aura. Recently, a self-administered VA rating scale (VARS) was developed based on the typical symptoms of VA12,13. It showed a high sensitivity and specificity for VA, and may allow a validated investigation of VA.

Probable migraine (PM) is a subtype of migraine that fulfills all but one criterion of migraine1. Its symptoms and associated disability differ from that of migraine, with a typically shorter attack duration, milder headache intensity, and lesser anxiety and depression4,15. PM affects 5%–15% of the general population annually16, and aura has been reported as a manifestation17. Although VA is a common symptom of migraine, reports of its impact on the clinical presentations of migraine and PM are currently scarce. If the clinical presentations of migraine and PM significantly differ according to the presence of VA, both conditions can be managed with more ease. Furthermore, no study has reported the prevalence of VA in individuals with PM in a general population-based setting. We hypothesized that the prevalence of VA in PM is similar to that in migraine, and the accompaniment of VA affects the clinical features of PM as it does of migraine. The present study aimed to compare the prevalence and impact of VA between PM and migraine using a nation-wide population-based sample in Korea.

Methods

Survey. The Circannual Change in Headache and Sleep (CHASE) study was a nation-wide, population-based survey that was conducted in October 2020 to evaluate the circannual changes in headache and sleep. The study had a baseline assessment phase, followed by longitudinal assessments performed every 3 months for over a year.
year. At the baseline assessment, the study included modules for the diagnosis of headache, depression, anxiety, insomnia, widespread pain, and obstructive sleep apnea. It also comprised modules for disability and impact of headaches, effects of acute headache treatment, quality of sleep, stress, and physical activity.

We used a two-stage, clustered random sampling method proportional to the population distribution of all Korean territories, except Jeju-do, based on the national population survey data of 2015. The target sample size was 3,000 and the estimated sampling error was ±1.8%. We conducted a web-based survey among adults aged 20–59 years with technical support from Hankook Research. This study used data collected during the baseline assessment phase of the CHASE study.

Migraine and PM diagnosis. Migraine was diagnosed based on the following diagnostic criteria for MO in the ICHD-3 (code 1.1): A. At least five attacks fulfilling criteria B–D; B. Headache attacks lasting for 4–72 h (when untreated or treated unsuccessfully); C. Headaches having at least two of the following four characteristics: (1) unilateral location, (2) pulsating quality, (3) moderate or severe pain intensity, and (4) aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs); D. Occurrence of at least one of the following during the headache: (1) nausea and/or vomiting or (2) photophobia and phonophobia; and E. Attacks not better accounted for by another ICHD-3 diagnosis. The diagnostic validity was evaluated by comparing the migraine diagnoses in the survey with the doctors’ diagnoses through additional telephone interviews. The sensitivity and specificity for the diagnosis of migraine were 75.0% and 88.2%, respectively.

PM was also diagnosed based on the ICHD-3; if a participant did not fulfill only one of the five criteria for migraine, they were classified as having PM (code 1.5). If a participant met the criteria for both tension-type headache (TTH) and PM, they were classified as having TTH according to the ICHD-3.

Because the diagnosis of MA (code 1.2) was made when a participant’s headache attack fulfilled the diagnostic criteria of both MA and MO, migraine in the present study refers to both MA and MO. Similarly, PM in the present study refers to both PM with aura (code 1.5.2) and PM without aura (code 1.5.1).

VA assessment. The self-reporting V ARS questionnaire was used for the assessment of VA. This questionnaire comprises the following five visual-symptom items (each scored 1–3): (1) duration of 5–60 min (3 points), (2) develops gradually in ≥5 min (2 points), (3) scotoma (2 points), (4) zig-zag lines (fortification; 2 points), and (5) unilateral (homonymous; 1 point). If the sum of the scores of these five items was ≥3, the participant was classified as having VA. If participants were noted to have migraine as well as VA, we classified them as having “migraine with VA.” If participants were noted to have migraine, but not VA, we classified them as having “migraine without VA.” We similarly classified participants as having PM with aura and having PM without aura. The self-reporting V ARS questionnaire showed a sensitivity of 96.4% and a specificity of 79.5%, respectively.

Impact and disability of migraine and PM. The impact of migraine and PM was assessed by the Headache Impact Test-6 (HIT-6) and Disability in migraine and PM was evaluated by the Migraine Disability Assessment (MIDAS)questionnaire. We used the Korean versions of the HIT-6 and MIDAS, which were previously validated for the Korean language.

Assessment of cutaneous allodynia, widespread pain, and acute treatment optimization. Cutaneous allodynia (CA) was assessed by the 12-item Allodynia Symptom Checklist (ASC-12), which measured interictal CA during the month prior to migraine occurrence via various symptoms of CA. Widespread pain was evaluated based on the Widespread Pain Index (WPI) in the 2016 American College of Rheumatology criteria for fibromyalgia. Acute treatment optimization was assessed using the 6-item version of the Migraine-Treatment Optimization Questionnaire (M-TOQ-6). A higher score on the M-TOQ-6 indicated a better response to acute treatment.

Assessment of anxiety, depression, and stress. Anxiety and depression were evaluated by the Generalized Anxiety Disorder-7 (GAD-7) questionnaire and the Patient Health Questionnaire-9 (PHQ-9), respectively. Stress was assessed by the Korean version of the Brief Encounter Psychosocial Instrument (BEPSI-K). The GAD-7 questionnaire, PHQ-9, and BEPSI-K were previously validated for the Korean language.

Ethical approval. The CHASE study was approved by the Institutional Review Board of the Severance Hospital, Yonsei University (approval no. 2020-0034-001). The participants provided written informed consent to participate in this study. All methods were performed in accordance with the Declaration of Helsinki and its subsequent amendments.

Statistical analyses. The 1-year prevalence of migraine was calculated as the number of cases per 100 persons. For continuous variables, normality was tested with the Kolmogorov–Smirnov test. After normality was confirmed, the Student’s t test or analysis of variance was used when appropriate. If the normality was not confirmed, the Mann–Whitney U test or the Kruskal–Wallis test was used. We used the chi-square test to compare the overall and sex-specific prevalence of VA between participants with migraine and those with PM. Clinical characteristics that were expressed as continuous variables were compared using multivariable linear regression analyses after adjustments for age and sex. Conversely, clinical characteristics that were expressed as categorical variables were compared using logistic regression analyses after adjustments for age and sex.
Statistical Package for Social Sciences (version 24.0; IBM, Armonk, NY, USA) was used for all statistical analyses. The statistical significance was set to \( p < 0.05 \). Because our web-based survey does not register as being complete without responses to all the questions, there were no missing data in our study.

**Results**

**Sample and survey.** The flow of participants throughout the study is summarized in Fig. 1. The cooperation rate in our study was 28.3% (3030/10,699). The sex, age, size of residential area, and educational level of our participants did not differ statistically significantly from that of the total population of Korea (Table 1). The survey was conducted in October 2020.

**Prevalence of migraine and PM.** Among the 3030 participants, 1,938 (63.7%) reported that they had experienced headaches during the previous year. Furthermore, 170 (5.6%) and 337 (11.1%) participants were classified as having migraine and PM, respectively (Fig. 1).
Prevalence of VA among participants with migraine and PM.

Among the 1,938 participants with headache, 406 (20.9%) had VARS scores ≥ 3 and were classified as having VA. Among the participants with migraine and PM, 50 (29.4%) and 82 (24.3%) were classified as having VA, respectively (Fig. 1). The prevalence of VA was similar between participants with migraine and participants with PM (p = 0.219).

The frequencies of VA among participants with migraine and those with PM are summarized in Table 2. The most common frequency of VA in headache attacks was 10%–24% in participants with migraine and in participants with PM. Occurrence of VA in 100% of all headache attacks was only reported in 4.0% and 1.2% of the participants with migraine and PM, respectively.

Sex-specific prevalence of VA in migraine and PM.

The sex-specific prevalence of VA in participants with migraine and those with PM is summarized in Fig. 2A and B, respectively. Among the 1,479 women analyzed, 32 (2.2%) and 46 (3.1%) participants were classified as having migraine with VA and PM with VA, respectively. Among the 1,551 men analyzed, 18 (1.2%) and 36 (2.3%) participants were classified as having migraine with VA and PM with VA, respectively. The prevalence of migraine with VA and migraine without VA showed a statistically significant difference among women (2.1% [32/1,479] vs. 6.6% [97/1,479], p < 0.001), but not among men (1.2% [18/1,551] vs. 1.5% [23/1,551], p = 0.886). However, the prevalence of PM with VA and PM without VA showed a statistically significant difference in both men (2.3% [36/1,551] vs. 6.1% [94/1,551], p < 0.001) and women (3.1% [46/1,479] vs. 10.9% [161/1,479], p < 0.001).

The female-to-male ratio for the prevalence of migraine with VA (1.86) was statistically significantly lower than that for the prevalence of migraine without VA (4.42) (p = 0.019). However, the female-to-male ratio for the prevalence of PM did not differ statistically significantly between participants with PM with VA (2.61) and those with PM without VA (3.50, p = 0.256).

Age-specific prevalence of VA in migraine and PM.

The age-specific prevalence of migraine with VA, migraine without VA, and overall migraine showed similar trends. The highest prevalence of all three was seen in participants in their 40s, followed by in participants in their 30s; the lowest prevalence was noted in participants in their 50s (Fig. 3A). The prevalence of PM with VA was also the highest in those in their 40s, followed by in

Table 2. Frequency of visual aura among all headache attacks in participants with migraine and probable migraine.

| Frequency of visual aura in all headache attacks | Migraine, N (%) | Probable migraine, N (%) |
|-------------------------------------------------|----------------|-------------------------|
| <10%                                            | 7 (14.0)       | 19 (23.2)               |
| 10–24%                                          | 18 (36.0)      | 29 (35.4)               |
| 25–50%                                          | 12 (24.0)      | 19 (23.2)               |
| 51–75%                                          | 8 (16.0)       | 11 (13.4)               |
| 76–99%                                          | 3 (6.0)        | 3 (3.7)                 |
| 100%                                            | 2 (4.0)        | 1 (1.2)                 |
| Total                                           | 50 (100.0)     | 82 (100.0)              |

Figure 2. Sex-specific prevalence of visual aura in migraine (A) and probable migraine (B). PM: probable migraine.
those in their 30s (Fig. 3B). However, the prevalence of PM with VA \((p = 0.232)\) and of PM without VA \((p = 0.466)\) did not differ statistically significantly with the age groups.

**Clinical characteristics of migraine and PM according to the presence of VA.** The number of headache days per month \((p = 0.044)\), HIT-6 scores \((p = 0.046)\), ASC-12 scores (CA; \(p = 0.043)\), BEPSI-K scores (stress; \(p < 0.001)\), and rate photophobia \((p = 0.038)\) were statistically significantly higher in participants with migraine with VA than in participants with migraine without VA (Table 3).

For PM, the headache frequency per month in participants with VA was statistically significantly higher than in participants without VA \((p = 0.004)\). Furthermore, CA \((p < 0.001)\), stress \((p = 0.001)\), anxiety (GAD-7; \(p < 0.001)\), depression (PHQ-9; \(p < 0.001)\), and widespread pain (WPI; \(p = 0.001)\) were more severe in participants having PM with VA than in those having PM without VA. The response to acute medications (M-TOQ-6) was less in participants having PM with VA than in those having PM without VA \((p = 0.003)\). Vomiting \((p = 0.011)\), photophobia \((p = 0.001)\), and phonophobia \((p < 0.001)\) were more prevalent in participants having PM with VA than in those having PM without VA (Table 3).

**Clinical characteristics of migraine and PM according to the frequency of VA in participants with migraine and PM.** We dichotomized the participants with migraine with VA and those with PM with VA according to the occurrence of VA in 51% of the headache attacks (set as the cut-off). Accordingly, 13 (26%) and 37 (74.0%) participants with migraine experienced VA in \(\geq 51\)% and < 51% of all headache attacks, respectively. Among the participants with PM, 15 (18.3%) and 67 (81.7%) experienced VA in \(\geq 51\)% and < 51% of all headache attacks, respectively.

Participants with migraine who experienced VA in \(\geq 51\)% of all headache attacks experienced a higher stress than those who experienced VA in < 51% of all headache attacks \((p = 0.045)\). Furthermore, compared to participants with migraine with VA in < 51% of all headache attacks, those with migraine with VA in \(\geq 51\)% of all headache attacks comprised more men \((p = 0.004)\). Other clinical characteristics did not differ statistically significantly between the two (Table 4).

Among the participants with PM with VA, those with VA in \(\geq 51\)% of all headache attacks had more widespread pain \((p = 0.028)\), depression \((p = 0.016)\), anxiety \((p = 0.013)\), stress \((p = 0.006)\), and poorer sleep quality \((p = 0.032)\) as compared with those with VA in < 51% of all headache attacks (Table 4).

**Clinical characteristics of migraine with VA and PM with VA.** We further compared the demographic and clinical characteristics between those with migraine with VA and those with PM with VA. Participants with migraine with VA had a more severe headache intensity (VAS score; \(p < 0.001)\), lesser unilateral pain \((p < 0.001)\), lesser nausea \((p = 0.004)\), and greater photophobia \((p = 0.002)\) and phonophobia \((p = 0.008)\) than participants with PM with VA (Supplementary Table 1).

**Discussion**

The main findings of the present study are as follows: (1) in a general population-based sample, 29.4% of the participants with migraine and 24.3% of the participants with PM experienced VA during the previous year; (2) the female-to-male ratio for the prevalence of migraine with VA was significantly lower than that for the prevalence of migraine without VA and the female-to-male ratios for the prevalence of PM with VA and PM without VA did not differ significantly; and (3) some symptoms of migraine and PM were more severe when accompanied with VA.

Traditionally, four types of migraine auras have been reported: VA, sensory aura, language aura, and motor aura\(^3\). These auras may appear alone or in combination with other auras. VA is the most common type (98% of the cases with MA), followed by sensory aura. Language and motor auras are uncommon\(^4\). Brainstem and retinal auras, which are rare, have also been included in ICHD-1\(^4\). Given that VA presents in most individuals

![Figure 3](https://www.nature.com/scientificreports/)
Table 3. Demographic and clinical characteristics according to the presence or absence of visual aura in migraine and probable migraine. PM: probable migraine, HA: headache, VAS: visual analogue scale, HIT-6: Headache Impact Test-6, MIDAS: Migraine Disability Assessment, WPI: Widespread Pain Index, FS: Fibromyalgia symptom severity score, PHQ-9: Patient Health Questionnaire-9, GAD-7: General Anxiety Disorder-7, ASC-12: 12-item Allodynia symptom checklist, BEPSI-K: Korean version of the Brief Encounter Psychosocial Instrument, M-TOQ-6: 6-item version of the Migraine-Treatment Optimization Questionnaire.

| Characteristics                      | Migraine with visual aura, N = 50 | Migraine without visual aura, N = 120 | P value | PM with visual aura, N = 82 | PM without visual aura, N = 255 | P value |
|--------------------------------------|-----------------------------------|--------------------------------------|---------|-----------------------------|---------------------------------|---------|
| Age (years)                          | 40.5 (33.8–47.5)                  | 40.0 (31.3–45.8)                     | 0.487   | 43.5 (33.0–50.0)            | 40.0 (30.0–49.0)                | 0.113   |
| Women                                | 32 (64.0)                         | 97 (80.8)                            | 0.019   | 46 (36.1)                   | 161 (63.1)                      | 0.255   |
| HA duration in hours                 | 12.0 (6.4–40.0)                   | 20.0 (6.0–48.0)                      | 0.456   | 0.1 (0.1–0.2)               | 0.1 (0.1–0.2)                   | 0.092   |
| Frequency                            | 4.0 (2.0–10.0)                    | 2.0 (1.0–4.8)                        | 0.320   | 2.0 (2.0–8.0)               | 2.0 (0.6–4.0)                   | 0.006   |
| HA days per month                    | 4.0 (2.0–10.0)                    | 3.0 (2.0–5.0)                        | 0.044   | 3.0 (2.0–5.0)               | 2.0 (1.0–4.0)                   | 0.007   |
| Severe HA days per month             | 2.50 (1.0–5.3)                    | 2.00 (1.0–5.0)                       | 0.051   | 2.0 (1.0–5.0)               | 1.0 (0.0–2.0)                   | < 0.001 |
| HA days with medication              | 21 (42.0)                         | 58 (48.3)                            | 0.622   | 0 (0.0)                     | 11 (4.3)                        | 0.997   |
| Moderate-to-severe intensity         | 50 (100.0)                        | 120 (100.0)                          | 1.000   | 55 (67.1)                   | 172 (67.4)                      | 0.949   |
| VAS score                            | 7.0 (7.0–8.0)                     | 7.00 (7.0–8.0)                       | 0.327   | 6.0 (4.0–7.0)               | 6.0 (4.0–7.0)                   | 0.604   |
| HIT-6 score                          | 50.0 (46.0–60.3)                  | 50.0 (45.0–56.8)                     | 0.046   | 49.5 (44.0–56.0)            | 50.0 (44.0–58.0)                | 0.509   |
| MIDAS score                          | 14.5 (8.8–32.3)                   | 12.5 (5.0–27.8)                      | 0.163   | 10.0 (5.0–26.3)             | 5.0 (2.0–12.0)                  | < 0.001 |
| Unilateral pain                      | 22 (44.0)                         | 69 (57.5)                            | 0.130   | 60 (72.3)                   | 181 (70.7)                      | 0.937   |
| Pulsating pain                       | 34 (68.0)                         | 73 (60.8)                            | 0.529   | 53 (64.6)                   | 196 (76.9)                      | 0.018   |
| Aggravation by movement              | 40 (80.0)                         | 98 (81.7)                            | 0.971   | 56 (68.3)                   | 128 (50.2)                      | 0.082   |
| Nausea                               | 31 (62.0)                         | 89 (74.2)                            | 0.520   | 69 (84.1)                   | 213 (83.5)                      | 0.967   |
| Vomiting                             | 24 (48.0)                         | 58 (48.3)                            | 0.577   | 43 (52.4)                   | 89 (34.9)                       | 0.011   |
| Photophobia                          | 42 (84.0)                         | 63 (89.2)                            | 0.038   | 48 (58.5)                   | 98 (38.4)                       | 0.001   |
| Phonophobia                          | 43 (86.0)                         | 94 (78.3)                            | 0.087   | 53 (64.6)                   | 113 (44.3)                      | < 0.001 |
| WPI                                  | 5.0 (3.0–7.0)                     | 4.0 (2.0–6.0)                        | 0.195   | 5.0 (4.0–7.0)               | 3.0 (2.0–6.0)                   | < 0.001 |
| FS                                   | 12.0 (10.0–15.0)                  | 12.0 (8.0–14.0)                      | 0.032   | 12.0 (9.8–13.3)             | 9.0 (6.0–12.0)                  | < 0.001 |
| PHQ-9 score                          | 8.0 (7.0–9.0)                     | 8.0 (5.0–9.0)                        | 0.755   | 9.0 (6.0–10.3)              | 7.0 (4.0–9.0)                   | < 0.001 |
| GAD-7 score                          | 8.0 (3.8–11.5)                    | 5.0 (3.0–9.0)                        | 0.085   | 7.0 (4.0–11.0)              | 4.0 (1.0–7.0)                   | < 0.001 |
| ASC-12 score                         | 3.0 (1.0–6.0)                     | 2.0 (0.0–4.7)                        | 0.043   | 2.0 (0.0–6.0)               | 0.0 (0.0–3.0)                   | < 0.001 |
| BEPSI-K score                        | 2.6 (2.0–3.2)                     | 2.2 (1.8–3.0)                        | 0.044   | 2.3 (2.0–3.0)               | 2.0 (1.0–2.8)                   | 0.001   |
| M-TOQ-6 score                        | 20.5 (16.3–24.0)                  | 22.0 (18.0–26.0)                     | 0.051   | 21.0 (17.3–25.0)            | 23.0 (21.0–26.5)                | 0.003   |

with MA and that the self-administered VARS has a high sensitivity for detecting VA, we assumed that most participants with MA were identified as having migraine with VA in the present study. Several studies have reported the prevalence of MA in migraine populations. The American Migraine Survey II, a nation-wide population study in the United States, reported that MA presented in 31% of the migraine population. An epidemiological study in Copenhagen, Denmark, demonstrated that 33.7% of the individuals with migraine were classified as having an aura. In a German nation-wide study, the prevalence of MA among individuals with migraine was 34.0%. However, studies in Asian countries revealed a somewhat lower proportion of MA in the migraine population. A population-based survey in Taipei, Taiwan, reported a prevalence of 12.5%, while a Malaysian community study reported a prevalence of 10.6%. Possible causes of the lower proportion of MA among migraine populations in previous Asian studies, as compared to in American and European studies, include differences in the ethnicity, lifestyle, and assessment methodology.

Although female predominance was found both in MA and MO, the female-to-male ratio for the prevalence of MA was significantly lower than that for the prevalence of MO in previous studies. The female-to-male ratio for the lifetime prevalence of MA was 1.5, whereas the female-to-male ratio for the prevalence of MO was 2.2 in a Danish population-based study. A Taiwanese study reported female-to-male ratios of 2.6 and 4.2 for the prevalence of MA and MO, respectively. The present study found similar results: female predominance was noted in migraine with VA and in migraine without VA. However, the female-to-male ratio for the prevalence of migraine with VA (1.86) was significantly lower than that for the prevalence of migraine without VA (4.42). Lower female predominance in MA than in MO indicates differences in the roles of sex hormones between the pathogeneses of MA and MO. A difference in the occurrence of attacks between MA and MO according to the female hormonal cycle was also reported; the study suggested that estrogen withdrawal was associated with attacks of MO and high plasma estrogen was associated with the occurrence of MA.
Table 4. Comparison of the demographic and clinical characteristics of the participants (with migraine and probable migraine) presenting with visual aura in <51% and >51% of all headache attacks. PM: probable migraine, HA: headache, VAS: visual analogue scale, HIT-6: Headache Impact Test-6, MIDAS: Migraine Disability Assessment, WPI: Widespread Pain Index, PHQ-9: Patient Health Questionnaire-9, GAD-7: Generalized Anxiety Disorder-7, ASC-12: 12-item Allodynia symptom checklist, BEPSI-K: Korean version Brief Encounter Psychosocial Instrument, M-TOQ-6: 6-item version of the Migraine-Treatment Optimization Questionnaire, PSQI: Pittsburgh Sleep Quality Index.

|                        | Migraine with visual aura in ≥51% of all headache attacks, N = 13 | Migraine with visual aura in <51% of all headache attacks, N = 37 | P value | PM with visual aura in ≥51% of all headache attacks, N = 15 | PM with visual aura in <51% of all headache attacks, N = 67 | P value |
|------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------|---------------------------------------------------------------|---------------------------------------------------------------|---------|
| Age (years)            | 38.0 (34.0–45.0)                                              | 41.0 (33.0–49.0)                                              | 0.595   | 37.0 (30.0–46.0)                                              | 45.0 (33.0–50.0)                                              | 0.117   |
| Women                  | 4 (30.8)                                                     | 28 (75.7)                                                    | 0.004   | 19 (66.7)                                                    | 36 (53.7)                                                    | 0.404   |
| Frequency              | 2.0 (0.75–8.0)                                               | 4.0 (2.0–10.0)                                               | 0.719   | 4.0 (1.0–8.0)                                               | 2.0 (2.0–8.0)                                               | 0.555   |
| HA days per month      | 2.0 (1.0–10.0)                                              | 5.0 (2.0–10.0)                                              | 0.282   | 3.0 (1.0–5.0)                                               | 2.0 (2.0–5.0)                                               | 0.336   |
| Severe HA days per month | 2.0 (1.0–5.0)                  | 3.0 (1.0–5.5)                                             | 0.381   | 3.0 (1.0–5.0)                                               | 2.0 (1.0–3.0)                                               | 0.876   |
| HA days with medication | 1.0 (0.0–15.0)                                             | 3.0 (1.0–5.0)                                             | 0.518   | 2.0 (0.0–5.0)                                               | 2.0 (1.0–5.0)                                               | 0.615   |
| Severe HA intensity    | 5 (38.5)                                                    | 16 (43.2)                                                   | 0.847   | 0 (0.0–0.0)                                                  | 0 (0.0–0.0)                                                  | 1.000   |
| VAS score              | 7.0 (7.0–8.0)                                               | 7.0 (7.0–8.0)                                               | 0.655   | 7.0 (4.0–8.0)                                               | 6.0 (4.0–7.0)                                               | 0.455   |
| HIT-6 score            | 50.0 (44.0–53.0)                                             | 54.0 (46.5–61.0)                                             | 0.545   | 46.0 (41.0–55.0)                                            | 50.0 (44.0–56.0)                                            | 0.328   |
| MIDAS score            | 11.0 (6.0–11.5)                                             | 15.0 (9.0–15.0)                                             | 0.417   | 11.0 (5.0–17.0)                                             | 10.0 (5.0–24.0)                                             | 0.200   |
| Unilateral pain        | 6 (46.2)                                                    | 16 (43.2)                                                   | 0.884   | 9 (60.0)                                                    | 51 (76.1)                                                    | 0.303   |
| Pulsating pain         | 8 (61.5)                                                    | 26 (70.3)                                                   | 0.275   | 9 (60.0)                                                    | 44 (65.7)                                                    | 0.752   |
| Aggravation by movement | 11 (84.6)                                                  | 29 (78.4)                                                   | 0.215   | 12 (88.4)                                                   | 44 (65.7)                                                    | 0.268   |
| Nausea                 | 9 (69.2)                                                    | 22 (59.5)                                                   | 0.574   | 12 (80.0)                                                   | 57 (85.1)                                                    | 0.702   |
| Vomiting               | 9 (69.2)                                                    | 15 (40.4)                                                   | 0.401   | 6 (40.0)                                                    | 37 (55.2)                                                    | 0.481   |
| Photophobia            | 13 (100.0)                                                  | 29 (78.4)                                                   | 0.998   | 12 (80.0)                                                   | 36 (53.7)                                                    | 0.071   |
| Phonophobia            | 9 (69.2)                                                    | 22 (59.5)                                                   | 0.121   | 11 (73.3)                                                   | 42 (62.7)                                                    | 0.567   |
| WPI                    | 3.0 (1.0–6.0)                                               | 6.0 (4.0–7.5)                                               | 0.559   | 7.0 (4.0–9.0)                                               | 4.0 (3.0–7.0)                                               | 0.028   |
| PHQ-9 score            | 9.0 (7.5–10.5)                                              | 8.0 (6.0–9.0)                                               | 0.400   | 10.0 (8.0–18.0)                                             | 8.0 (6.0–9.0)                                               | 0.016   |
| GAD-7 score            | 9.0 (4.5–10.5)                                              | 8.0 (3.0–13.0)                                             | 0.754   | 12.0 (5.0–15.0)                                             | 6.0 (4.0–9.0)                                               | 0.013   |
| ASC-12 score           | 4.0 (2.5–8.0)                                               | 3.0 (0.5–8.0)                                               | 0.675   | 4.0 (2.0–8.0)                                               | 2.0 (0.0–6.0)                                               | 0.572   |
| BEPSI-K score          | 3.0 (2.7–3.8)                                               | 2.6 (2.0–3.0)                                               | 0.045   | 3.2 (2.2–4.0)                                               | 2.2 (2.0–2.8)                                               | 0.006   |
| M-TOQ-6 score          | 20.5 (15.3–22.8)                                            | 20.0 (16.5–24.3)                                            | 0.555   | 21.0 (18.0–26.0)                                            | 21.0 (17.0–25.0)                                            | 0.827   |
| PSQI                   | 9.0 (7.5–10.0)                                              | 7.0 (5.5–9.0)                                               | 0.130   | 10.0 (7.0–10.0)                                             | 7.0 (5.0–9.0)                                               | 0.032   |

The female-to-male ratio for the prevalence of PM, according to the presence of aura, has rarely been reported. This study found that female predominance in the prevalence of PM was less prominent as compared to that in the prevalence of migraine, and the female-to-male ratios did not differ significantly with the presence or absence of VA. Therefore, findings regarding the female-to-male ratios for the prevalence of PM propose different roles of sex hormones in the pathogenesis of PM.41,42 The present study found a higher frequency of headache and more severe CA in participants with migraine with VA than in those with migraine without VA. One possible explanation for the differences in the clinical presentation of migraine with respect to the presence or absence of VA is the difference in the mechanism of migraine between the two. Cortical spreading depression (CSD) has been considered a key mechanism of VA.40,41 Although there are some controversies,42 the role of CSD in MO is not well understood.43,44 Our study findings suggest that CSD might be involved in some migraine attacks in individuals with migraine with VA; this may be responsible for the differences in some clinical characteristics between participants with migraine with VA and those with migraine without VA.

The MIDAS scores of participants with PM with VA were higher than those of participants with PM without VA. Conversely, the MIDAS scores of participants with migraine with VA did not differ significantly from those of participants with migraine without VA. This discrepancy may be due to differences in the severity of the symptoms and disability between migraine and PM. The symptoms and disability of participants with PM were milder than those of participants with migraine.43,45 Because the symptoms of migraine were severe enough, an exacerbation of some symptoms with the accompaniment of VA did not affect disability. In PM, which was associated with milder disability, the worsening of symptoms due to VA accompaniment may have exacerbated disability significantly.

The present study has several limitations. First, the cooperation rate of the present study was not high at 28.3%. Such a low cooperation rate in a web-based survey has already been reported. The Chronic Migraine Epidemiology and Outcomes study was a nation-wide web-based survey for migraine in the USA, and its cooperation rate (16.5%) was lower than that of the American Migraine Prevalence and Prevention survey (65.8%), a traditional mailed survey.46 Nevertheless, the distributions of age, sex, size of residential area, and educational
level in our sample were not significantly different from those of the total population of Korea. In addition, the prevalence of migraine (5.6%) and PM (11.3%) in our study were similar to those reported in previous studies in Korea (4.7%–9.1%) and other Asian countries (6.1%–12.8%) [32,36,38]. Second, although we used data from a nation-wide population-based study with a large sample size, an external validity is needed for the generalizability of our findings. Common issues that limit external validity include selection biases, aptitude, treatment interactions, and so on [47]. Therefore, the findings of the present study should be verified in various populations.

The strengths of the present study are as follows. First, we used a validated instrument to assess the presence of VA. Previous epidemiological studies evaluated aura symptoms using questionnaires that were not validated for the detection of aura. The present study used the self-administered VARS questionnaire, which has been validated by comparing its results to a doctor’s diagnosis of VA [12]. Second, we evaluated the prevalence and impact of VA in PM in addition to that in migraine. PM is a prevalent headache disorder that fulfills all but one criterion of migraine. Yet, the prevalence and impact of VA have rarely been documented.

In conclusion, the present study evaluated the prevalence and impact of VA in migraine and PM in a general population-based sample using a validated instrument. The prevalence of VA was not significantly different between migraine and PM. Some symptoms and comorbidities of migraine and PM with VA were more severe as compared with those of migraine and PM without VA.

Data availability
Anonymized data relevant to this study will be shared upon request with a qualified investigator after appropriate institutional review board approvals.

Received: 30 August 2021; Accepted: 20 December 2021
Published online: 10 January 2022

References
1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia* 38, 1–211 (2018).
2. Eriksen, M. K., Thomsen, L. L., Andersen, I., Nazim, F. & Olesen, J. Clinical characteristics of 362 patients with familiar migraine with aura. *Cephalalgia* 24, 564–575 (2004).
3. Russell, M. B. & Olesen, J. A nosographic analysis of the migraine aura in a general population. *Brain* 119(Pt 2), 355–361 (1996).
4. Viana, M. et al. Clinical features of migraine aura: Results from a prospective diary-aided study. *Cephalalgia* 37, 979–989 (2017).
5. Hansen, J. M. & Charles, A. Differences in treatment response between migraine with aura and migraine without aura: Lessons from clinical practice and RCTs. *J. Headache Pain* 20, 96 (2019).
6. Russell, M. B., Rasmussen, B. K., Fenger, K. & Olesen, J. Migraine without aura and migraine with aura are distinct clinical entities: A study of four hundred and eighty-four male and female migraineurs from the general population. *Cephalalgia* 16, 239–245 (1996).
7. Vijiaratnam, N. et al. Migraine: Does aura require investigation? *Clin. Neurol. Neurosurg.* 148, 110–114 (2016).
8. Hauge, A. W., Kirchmann, M. & Olesen, J. Trigger factors in migraine with aura. *Cephalalgia* 30, 346–353 (2010).
9. Wang, S. J., Fuh, J. L., Young, Y. H., Lu, S. R. & Shia, B. C. Prevalence of migraine in Taipei, Taiwan: A population-based survey. *Cephalalgia* 20, 566–572 (2000).
10. Sakai, N. & Igarashi, H. Prevalence of migraine in Japan: A nationwide survey. *Cephalalgia* 17, 15–22 (1997).
11. Buse, D. C. et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. *Headache* 53, 1278–1293 (2013).
12. Kim, B. K., Cho, S., Kim, H. Y. & Chu, M. K. Validity and reliability of the self-administered Visual Aura Rating Scale questionnaire for aura diagnosis: A prospective clinic-based study. *Headache* 61, 863–871 (2021).
13. Eriksen, M. K., Thomsen, L. L. & Olesen, J. The Visual Aura Rating Scale (VARS) for migraine aura diagnosis. *Cephalalgia* 25, 801–810 (2005).
14. Kim, B. K., Chung, Y. K., Kim, J. M., Lee, K. S. & Chu, M. K. Prevalence, clinical characteristics and disability of migraine and probable migraine: A nationwide population-based survey in Korea. *Cephalalgia* 33, 1106–1116 (2013).
15. Song, T. J. et al. Anxiety and depression in probable migraine: A population-based study. *Cephalalgia* 37, 845–854 (2017).
16. Silberstein, S. et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. *Cephalalgia* 27, 229–229 (2007).
17. Eriksen, M. K., Thomsen, L. L. & Olesen, J. New international classification of migraine with aura (ICHD-2) applied to 362 migraine patients. *Eur. J. Neurol.* 11, 583–591 (2004).
18. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. *Cephalalgia* 8 Suppl 7, 1–96 (1988).
19. Kasinski, M. et al. A six-item short-form survey for measuring headache impact: The HIT-6. *Qual. Life Res.* 12, 963–974 (2003).
20. Stewart, W. F. et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. *Neurology* 53, 988–994 (1999).
21. Lee, H., Chung, C., Song, H. & Park, H. The Reliability and Validity of the MIDAS (Migraine Disability Assessment) Questionnaire for Korean Migraine Sufferers. *J. Korean Neurol. Assoc.* 18, 287–291 (2000).
22. Lipton, R. B. et al. Cutaneous allodynia in the migraine population. *Ann. Neurol.* 63, 148–158 (2008).
23. Wolfe, F. et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Semin. Arthritis Rheum.* 46, 319–329 (2016).
24. Serrano, D., Buse, D. C., Manack Adams, A., Reed, M. L. & Lipton, R. B. Acute treatment evaluation in epidemic and chronic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. *Headache* 55, 502–518 (2015).
25. Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression severity measure. *J. Gen. Intern. Med.* 16, 606–613 (2001).
26. Kroenke, K., Spitzer, R. L., Williams, J. B., Monahan, P. O. & Löwe, B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann. Intern. Med.* 147, 317–325 (2007).
27. Kroenke, K. & Spitzer, R. L. The PHQ-9: A new depression diagnostic and severity measure. *Psychiatr. Ann.* 32, 509–515 (2002).
28. Huh, B. Y. et al. Original articles: The Validity of Modified Korean - translated BEPSI (Brief Encounter Psychosocial Instrument) as an instrument of stress measurement in outpatient clinic. *J. Korean Acad. Fam. Med.* 17, 42–53 (1996).
29. Frank, S. H. & Zyzanski, S. J. Stress in the clinical setting: The Brief Encounter Psychosocial Instrument. *J. Fam. Pract.* 26, 533–539 (1988).
30. Seo, J. G. & Park, S. P. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. *J. Headache Pain* 16, 97 (2015).
Institutional affiliations.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and is available at www.nature.com/reprints.

Reprints and permissions information and requests for materials should be addressed to M.K.C.

Correspondence 10.1038/s41598-021-04250-3.

The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-04250-3.

Supplementary Information
Additional information

This study was supported by a grant from Korean Neurological Association (KNA-20-MI-13) and the National Research Foundation of Korea (NRF) grant from the Korean government (MSIT) [2019R1F1A1053841].

Competing interests
MKC was a site investigator for a multi-center trial sponsored by Otsuka Korea, Novartis International AG, and Eli Lilly and Company. He worked as an advisory member for Teva and has received lecture honoraria from Allergan Korea, Handok-Teva, and Yuyu Pharmaceutical Company in the past 24 months. He received grants from the Yonsei University College of Medicine (2018-32-0037) and the National Research Foundation of Korea (2019R1F1A1053841). KMK, BK, WL, HH, and KH declare no potential conflict of interest.

Acknowledgements
This study was supported by a grant from Korean Neurological Association (KNA-20-MI-13) and the National Research Foundation of Korea (NRF) grant from the Korean government (MSIT) [2019R1F1A1053841].

Author contributions
Conception and coordination of the study: K.M.K., B.K., and M.K.C.; Acquisition of data: K.M.K., K.K., WL., H.H., K.H., and M.K.C.; Analysis and interpretation of data: K.M.K., B.K, and M.K.C.; Data review and statistical analysis: K.M.K., B.K, and M.K.C.; Manuscript preparation: K.M.K., B.K., and M.K.C.; Critical revision of the manuscript: B.K. and M.K.C.; and Manuscript approval: all authors.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022